Retinitis pigmentosa is a genetic disorder that causes degeneration of the light-sensing cells in the retina. Generally diagnosed in childhood or early adolescence, patients gradually lose peripheral and night vision, often becoming legally blind by young adulthood.
With the exception of a subset of patients who present a specific genetic mutation and can be treated with gene therapy, there is no cure for the condition. Cases are addressed by measures to slow degeneration and preserve what is left of the vision.
Optogenetics — the technology just recognized with a Nobel Prize — could offer hope, according to a new paper published on Wednesday in the New England Journal of Medicine.
